Explore stories from Atlantic Canada.
Everything to know about the April 8 eclipse in Atlantic Canada | SaltWire #eclipse | SaltWireCOPENHAGEN - The parent of Wegovy producer Novo Nordisk has refiled an application to the U.S. Federal Trade Commission for approval of a $16.5 billion deal to buy manufacturing subcontractor Catalent, a spokesperson said on Monday.
Novo Nordisk Foundation said last month it had agreed to buy Catalent to boost output of the weight-loss drug Wegovy. After the deal closes, it would sell three of Catalent's fill-finish sites on to Novo Nordisk for $11 billion.An application was submitted to U.S. anti-trust authorities on March 4. But"following informal discussions with the FTC staff", the company withdraw and filed a new application on April 2, a Catalent SEC filing dated April 3 showed.
A Novo Foundation spokesperson confirmed to Reuters that the company"has resubmitted the application to give authorities more time". Novo had said the deal was expected to be completed towards the end of 2024. The spokesperson declined to comment on whether that was still possible and also declined to comment on why the application had been refiled.
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Eli Lilly and Novo Nordisk's Diabetes Drugs Being Studied for Other Health BenefitsEli Lilly's Mounjaro and Novo Nordisk's Ozempic and Wegovy are being investigated for potential health benefits beyond diabetes treatment. A study is examining whether Novo's Wegovy can reduce alcohol intake in patients with early Alzheimer's disease. Another study is testing Novo's semaglutide in combination with clot removal therapy for stroke patients. Lilly is also conducting research on the effects of their drugs on Alzheimer's disease and obesity.
Read more »
Tesla, Lucid, Novo Nordisk: Trending tickersEV makers Tesla (TSLA), Rivian (RIVN), and NIO (NIO) have all received a downgrade from Mizuho Securities to Neutral citing near-term demand and challenges...
Read more »
Novo Nordisk to buy Cardior Pharmaceuticals for up to $1.1 billionDenmark's Novo Nordisk on Monday said it has agreed to buy Cardior Pharmaceuticals for up to 1.03 billion euros ($1.11 billion) to strengthen its...
Read more »
Novo Nordisk Agrees to Buy Cardior Pharma for Up to €1 BillionNovo Nordisk A/S agreed to buy Cardior Pharmaceuticals for up to €1 billion ($1.1 billion) as the Danish maker of weight-loss drugs continues to expand into treatments for cardiovascular disease.
Read more »
Ares, Blue Owl Lead $4.8 Billion Private Debt for Catalent DealAres Management Corp. and Blue Owl Capital Inc. are leading a group of private credit lenders providing $4.8 billion of debt financing for the acquisition of pharmaceuticals manufacturer Catalent Inc., according to people with knowledge of the matter.
Read more »
Ares, Blue Owl Lead $4.8 Billion Private Debt for Catalent Deal(Bloomberg) -- Ares Management Corp. and Blue Owl Capital Inc. are leading a group of private credit lenders providing $4.8 billion of debt financing for the...
Read more »